Clinical trials for pharmacogenomics testing for warfarin dosing: Relevance to general community practices

Genetics in Medicine

Volumn 13, Issue 6, 2011, Pages 505-508

  Sidiropoulos, Nikoletta ^a   Wu, Alan H B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VITAMIN K GROUP; WARFARIN;

AGE DISTRIBUTION; ANTICOAGULANT THERAPY; COMMUNITY CARE; COMORBIDITY; CONGESTIVE HEART FAILURE; DEMOGRAPHY; DIET; DOSE CALCULATION; DRUG MONITORING; DRUG USE; EDUCATIONAL STATUS; FOOD PROCESSING; GENETIC TRAIT; GENOTYPE; HEALTH CARE ACCESS; HEALTH LITERACY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MEDICAL HISTORY; MEDICATION THERAPY MANAGEMENT; NOTE; NUTRITIONAL COUNSELING; PATIENT ATTITUDE; PATIENT EDUCATION; PHARMACOGENOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOCIAL PSYCHOLOGY; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; VALVULAR HEART DISEASE; VENOUS THROMBOEMBOLISM; VITAMIN INTAKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; PHARMACOGENETICS; TREATMENT OUTCOME; WARFARIN;

EID: 79959260078     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1097/GIM.0b013e31821db51a     Document Type: Note

References (28)

1. Burmester JK, Berg RL, Yale SH, et al. A randomized controlled trial of genotype-based coumadin initiation. Genet Med 2011;13;509-518.
2. Jonas DE, Bryant Shilliday B, Laundon WR, Pignone M. Patient time requirements for anticoagulation therapy with warfarin. Med Decis Making 2010;30:206-216.
3. Rose J, Ozonoff A, Grant RW, et al. Epidemiology of subtherapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes 2009; 2:591-597.
4. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-Analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009;15:244-252.
5. Platt AB, Russell Localio A, Brensinger CM, et al. Can we predict daily adherence to warfarin? Chest 2010;137:883-889.
6. Cruess DG, Russell Localio A, Platt AB, et al. Patient attitudinal and behavioral factors associated with warfarin non-adherence at outpatient anticoagulation clinics. Int J Behav Med 2010;17:33-42.
7. Palareti G, Legnani C, Guazzaloca G, et al. Risk factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol 2005; 129:72-78. (Pubitemid 40524054)
8. Oden A, Fahlen M, Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res 2006;117:493-499. (Pubitemid 43326133)
9. Wysowski DK, Nourjah P, Swartz L. Bleeding complication with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007;167:1414-1419. (Pubitemid 47052441)
10. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-17.
11. Reynolds MW, Fahrbach K, Hauch O, et al. warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004;126:1938-1945. (Pubitemid 39644002)
12. Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials for patient self-management. J Thromb Thrombolysis 2000;9:283-292. (Pubitemid 30201262)
13. Chamberlain MA, Sageser NA, Ruiz D. Comparison of anticoagulation clinic patient outcomes with outcomes from traditional care in a family medicine clinic. J Am Board Fam Pract 2001;14:16-21. (Pubitemid 33605759)
14. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998;158:1641-1647. (Pubitemid 28371187)
15. van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control, a systematic review and metaregression. Chest 2006;129:1155-1166.
16. Levi M, Richard Hobbs FD, Jacobson AK, et al. Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives. Semin Thromb Hemost 2009;35:527-542.
17. Hirsh J, Guyatt G, Albers GW, et al. for the American College of Chest Physicians. Executive summary: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133(suppl 6):S71-S109.
18. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation, does efficacy in clinical trials translate into effectiveness in practice. Arch Intern Med 1994;154:1945-1953. (Pubitemid 24276379)
19. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin-a randomized controlled trial. Ann Intern Med 2000;133:687-695.
20. Rombouts EK, Rosendaal FR, van der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost 2007;5: 2043-2048. (Pubitemid 47450022)
21. Rombouts EK, Rosendaal FR, van der Meer FJ. Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy. Br J Haematol 2010;149:598-605.
22. Reese AM, Farnett LE, Lyons RM, et al. Low-dose vitamin K to augment anticoagulation control. Pharmacotherapy 2005;25:1746-1751. (Pubitemid 41790098)
23. Shearer MJ, Bach A, Kohlmeier M. Chemistry, nutritional sources, tissue distribution and metabolism of vitamin K with special reference to bone health. J Nutr 1996;126:1181S-1186S. (Pubitemid 26105655)
24. Elder SJ, Haytowitz DB, Howe J, et al. Vitamin K contents of meat, dairy, and fast food in the U.S. diet. J Agric Food Chem 2006;54:463-467.
25. Booth SL, Suttie JW. Dietary intake and adequacy of vitamin K1. J Nutr 1998;128:785-788.
26. Weizmann N, Peterson JW, Haytowitz D, et al. Vitamin K content of fast foods and snack foods in the US diet. J Food Comp Anal 2004;17:379-384. (Pubitemid 38787194)
27. Kamali F, Pirmohamed M. The future prospects of pharmacogenomics in oral anticoagulation therapy. Br J Clin Pharm 2006;61:746-751. (Pubitemid 43794805)
28. Joo J, Geller NL, French B, Kimmel SE, Rosenberg Y, Ellenberg JH. Prospective alpha allocation in the clarification of optimal anticoagulation through genetics (COAG) trial. Clin Trials 2010;7:597-604.